| 摘要 |
<p>Disclosed is the use of a fluid drug formulation in the manufacture of a medicament for the treatment of an ocular disease selected from uveitis, glaucoma, diabetic macular edema, diabetic retinopathy, macular degeneration, choroidal neovascularization or cytomegalovirus retinitis, wherein the medicament is formulated to be delivered via a hollow microneedle, the microneedle having a beveled tip end with an opening, wherein the medicament is formulated for being infused over a period of time through the inserted microneedle and into the suprachoroidal space of the eye, wherein the medicament is formulated to flow posterior to the equator of the eye during the infusion period.</p> |
